Cyclacel Pharmaceuticals, Inc. (CYCC)
NASDAQ: CYCC · Real-Time Price · USD
0.317
-0.014 (-4.11%)
At close: Dec 20, 2024, 4:00 PM
0.333
+0.016 (4.91%)
After-hours: Dec 20, 2024, 7:10 PM EST
Cyclacel Pharmaceuticals Employees
Cyclacel Pharmaceuticals had 12 employees as of December 31, 2019. The number of employees decreased by 2 or -14.29% compared to the previous year.
Employees
12
Change (1Y)
-2
Growth (1Y)
-14.29%
Revenue / Employee
$6,167
Profits / Employee
-$1,123,417
Market Cap
2.00M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
cbdMD | 52 |
Aptevo Therapeutics | 40 |
Bluejay Diagnostics | 10 |
TransCode Therapeutics | 10 |
Phio Pharmaceuticals | 9 |
Tivic Health Systems | 9 |
Dermata Therapeutics | 8 |
Virpax Pharmaceuticals | 7 |
CYCC News
- 16 days ago - Cyclacel Pharmaceuticals Announces Its Exploration of Potential Strategic Alternatives and Reduction of Operating Costs - GlobeNewsWire
- 5 weeks ago - Cyclacel Pharmaceuticals Announces Closing of Exercise of Warrants for $2.1 Million Gross Proceeds - GlobeNewsWire
- 5 weeks ago - Cyclacel Pharmaceuticals Announces Exercise of Warrants for $2.1 Million Gross Proceeds - GlobeNewsWire
- 5 weeks ago - Cyclacel Pharmaceuticals Reports Third Quarter Financial Results and Provides Business Update - GlobeNewsWire
- 2 months ago - Cyclacel Pharmaceuticals Announces That Nasdaq Granted an Extension to Regain Compliance With the Equity Standard Rule - GlobeNewsWire
- 2 months ago - Cyclacel Pharmaceuticals Reports New Clinical Data from Ongoing, Phase 2 Study of Oral Fadraciclib at the 2024 EORTC-NCI-AACR Symposium - GlobeNewsWire
- 2 months ago - Cyclacel Pharmaceuticals to Present New Clinical Data From Phase 2 Study of Oral Fadraciclib at the 2024 EORTC-NCI-AACR Symposium - GlobeNewsWire
- 3 months ago - Cyclacel Pharmaceuticals Announces Completion of Enrollment in the Biomarker-Enriched Patient Cohort of Its Phase 2 Study - GlobeNewsWire